Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.80 |
| ▸ | BACE1 | P56817 | 4/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.71 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.70 |
| ▸ | MAOB | P27338 | 2/20 | 0.67 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.67 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | APP | P05067 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL527827 | 1.00 | GSK3B (0.80) | GSK3BBACE1KDM4EALDH1A1PKM | |
| SCHEMBL8740053 | 1.00 | GSK3B (0.80) | GSK3BBACE1KDM4EALDH1A1PKM | |
| Hydrochloric Acid SCHEMBL7054738 | 0.98 | GSK3B (0.78) | GSK3BBACE1KDM4EALDH1A1PKM | |
| SCHEMBL5947453 | 0.94 | KDM4E (0.71) | GSK3BBACE1KDM4EALDH1A1PKM | |
| SCHEMBL5947456 | 0.94 | KDM4E (0.71) | GSK3BBACE1KDM4EALDH1A1PKM | |
| SCHEMBL7999153 | 0.90 | GSK3B (0.83) | GSK3BBACE1KDM4EABCG2MAOB | |
| SCHEMBL7999149 | 0.90 | GSK3B (0.83) | GSK3BBACE1KDM4EABCG2MAOB | |
| SCHEMBL8889841 | 0.89 | GSK3B (0.69) | GSK3BBACE1KDM4EALDH1A1PKM | |
| SCHEMBL8889847 | 0.89 | GSK3B (0.69) | GSK3BBACE1KDM4EALDH1A1PKM | |
| SCHEMBL1481376 | 0.88 | KDM4E (0.77) | GSK3BBACE1KDM4EALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11347109-B2 | Multilayer liquid crystal film, polarizing plate and method for preparing polarizing plate | LG CHEM, LTD. (KR) | 2022-05-31 | — | — | US | claimed |
| CN-110437758-A | A kind of anti-highly basic high temperature resistant easy-stripping type PO base protective film pressure-sensitive adhesive formula and preparation method thereof | KUNSHAN BYE MACROMOLECULE MAT CO LTD | 2019-11-12 | — | — | CN | claimed |
| EP-2562189-B9 | CATALYST COMPONENT FOR OLEFIN POLYMERIZATION REACTION AND CATALYST COMPRISING SAME | CHINA PETROLEUM & CHEM CORP (CN) | 2018-09-26 | — | — | EP | claimed |
| CN-108219702-A | A kind of novel acrylic pressure-sensitive adhesive protective film | 上海保立佳新材料有限公司 | 2018-06-29 | — | — | CN | claimed |
| EP-2562189-B1 | CATALYST COMPONENT FOR OLEFIN POLYMERIZATION REACTION AND CATALYST COMPRISING SAME | CHINA PETROLEUM & CHEMICAL (CN) | 2015-06-24 | — | — | EP | claimed |
| US-20250000979-A1 | TRIPLET-TRIPLET ENERGY TRANSFER WITH LIGHT EXCITATION AT LONG WAVELENGTHS AND METHODS THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2025-01-02 | — | — | US | disclosed |
| US-20240415985-A1 | PHOTOCLEAVABLE PRODRUG-BASED NANOMEDICINE FOR IN-SITU MONITORABLE CANCER THERAPY | THE UNIVERSITY OF HONG KONG (CN) | 2024-12-19 | — | — | US | disclosed |
| CN-119097715-A | Triplet-triplet energy transfer excited by long wavelength light and method thereof | 香港大学 | 2024-12-10 | — | — | CN | disclosed |
| CN-118159292-A | Photopheresis prodrug-based nanomedicines for in situ monitorable cancer therapy | 香港大学 | 2024-06-07 | — | — | CN | disclosed |
| EP-3495349-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2023-06-28 | — | — | EP | disclosed |
| WO-2023066076-A1 | PHOTOCLEAVABLE PRODRUG-BASED NANOMEDICINE FOR IN-SITU MONITORABLE CANCER THERAPY | THE UNIVERSITY OF HONG KONG (CN) | 2023-04-27 | — | — | WO | disclosed |
| US-11372288-B2 | Multilayer liquid crystal film, polarizing plate and method for preparing polarizing plate | LG CHEM, LTD. (KR) | 2022-06-28 | — | — | US | disclosed |
| US-5654462-A | CATALYTIC HYDROGENATION OF OLEFINS; ANTIBIOTICS; ENZYME INHIBITOR | MONSANTO COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0299457-B1 | Novel benzothiophenes having antiallergic activity and both novel and other selected benzothiophenes having activity for treating acute respiratory distress syndrome | WARNER LAMBERT CO (US) | 1994-09-21 | — | — | EP | disclosed |
| EP-0598754-A1 | INDOLES | Pfizer Limited (GB) | 1994-06-01 | — | — | EP | disclosed |
| WO-1993002051-A1 | INDOLES | PFIZER LIMITED (GB) | 1993-02-04 | — | — | WO | disclosed |
| US-4931459-A | ADMINISTERING SUBSTITUTED BENZOTHIOPHENES OR BENZOFURANS | WARNER-LAMBERT COMPANY (US) | 1990-06-05 | — | — | US | disclosed |
| US-4910317-A | Containing a 5-amidetetrazole substitution in position 2 | WARNER-LAMBERT COMPANY (US) | 1990-03-20 | — | — | US | disclosed |
| US-3995054-A | MITICIDES | ZOECON CORPORATION (US) | 1976-11-30 | — | — | US | disclosed |
| US-3975429-A | Cyclopropanemethyl esters of cinnamic acid and derivatives thereof | ZOECON CORPORATION (US) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415985-A1 | PHOTOCLEAVABLE PRODRUG-BASED NANOMEDICINE FOR IN-SITU MONITORABLE CANCER THERAPY | HCCS, CRY1, PIN1 | GSK3B 3529/4885BACE1 778/4885KDM4E 3857/4885 |
| US-20250000979-A1 | TRIPLET-TRIPLET ENERGY TRANSFER WITH LIGHT EXCITATION AT LONG WAVELENGTHS AND METHODS THEREOF | TTPA, TST, TK1 | GSK3B 4206/4885BACE1 593/4885KDM4E 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.